ITM Power: Government Cash and an Insider Bet Send Mixed Signals

UK clears £86.5M grant and equity for ITM Power's gigawatt electrolyser plant. New Chronos stack boosts efficiency; director Warren East buys shares amid volatile stock performance.

London has formally unlocked the funding for ITM Power’s next-generation electrolyser factory, but the market is still wrestling with the gap between long-term ambition and near-term turbulence. The Department for Energy Security and Net Zero has awarded the company a £46.5 million grant (roughly €54.5 million) to build a gigawatt-scale production line for its new “Chronos” stack in Sheffield, with an additional £40 million equity injection from Great British Energy now also secured. The package, worth a combined £86.5 million, had been awaiting clearance from the Competition and Markets Authority’s Subsidy Advice Unit; that hurdle has now been cleared, giving the go-ahead for a facility that aims to come fully online in 2028.

The Chronos design is at the heart of the expansion. ITM Power says the stack uses 50% fewer components than its predecessor while doubling power density to 2.5 MW per square metre. Chief executive Dennis Schulz called the grant a decisive moment for Britain’s hydrogen industry, positioning Sheffield as a central manufacturing hub. The company will keep selling its existing Trident platform alongside the new technology, with supply agreements already in place for 20 MW with MorGen Energy and 120 MW with Uniper. Those contracts form the revenue base that ITM hopes to scale as Chronos moves toward serial production.

Amid this long-term narrative, a director has put his own money on the table. Non-executive director Warren East, the former ARM and Rolls-Royce chief, bought 172,000 shares on 4 July. The purchase – recorded at the London Stock Exchange on 8 July – was worth several hundred thousand pounds at the prevailing price. Insider buying is often read as a vote of confidence in the strategic direction, and East’s timing is notable: the stock had already fallen sharply from its 52-week high of €2.58, hit on 29 May, and the grant decision was still pending. Yet the market reaction has been muted at best. The share price closed Wednesday at €1.36, sliding further from the peak, before edging up 2.06% to €1.39 on Thursday after the grant confirmation. Over the past month the stock has lost nearly 9%, and the weekly decline stands at 3.94%.

The longer-term picture is more dramatic. ITM Power’s shares have still surged 91.59% since the start of the year, though that masks a correction from the May high. The current price sits about 30% above the 200-day moving average of €1.07 but remains 46% below the record. On a 12-month view the gain is 36.54%. Volatility remains extreme: the annualised 30-day figure hovers around 107%, underscoring that even a government-backed catalyst can trigger only a modest bounce in a stock that routinely swings by double digits.

Operationally, the company is making progress even as losses persist. In the first half of the financial year ITM posted a record revenue of £18 million, the highest in its history, and its order book had swelled to £152 million at the end of the previous reporting period, with management pointing to a rising share of profitable contracts. The partnership with Rheinmetall on the Giga PtX synthetic-fuels project remains a key item on analysts’ watch lists. Berenberg recently raised its target price to 200 pence (approximately €2.35), citing the opening of new end-markets as a growth driver.

The immediate challenge for ITM Power is converting technological breakthroughs and government support into a steady stream of commercial orders before the Sheffield line is ready. The Chronos facility is the next major milestone, but the company must also navigate a capital-intensive ramp-up that will keep it loss-making for some time. With a market cap of €914 million and a relatively low debt burden, the balance sheet offers a cushion – but the stock’s wild swings suggest that investors are still pricing in a high degree of execution risk. The next clear catalyst will be the CMA’s final sign-off on the grant subsidy, expected shortly, after which the focus shifts entirely to delivery.